Literature DB >> 3540826

Decreased baseline beta-lactamase production and inducibility associated with increased piperacillin susceptibility of Pseudomonas cepacia isolated from children with cystic fibrosis.

C Chiesa, P H Labrozzi, S C Aronoff.   

Abstract

The incidence of pulmonary infections in children with cystic fibrosis caused by Pseudomonas cepacia, an organism which may possess an inducible beta-lactamase, has increased since 1978. Seven of 13 sputum isolates of P. cepacia from children with cystic fibrosis were classified as inducible by quantitative enzyme production following preincubation with 100, 200, or 400 micrograms/ml of cefoxitin. The recovery of inducible strains tended to be associated with recent ceftazidime therapy. Susceptibility to aztreonam, ceftazidime, and piperacillin alone or combined with the beta-lactamase inhibitors. YTR 830 or sulbactam, and isoelectric focusing for beta-lactamase were performed. Inducible isolates produced significantly more beta-lactamase than noninducible strains with or without the addition of cefoxitin. Noninducible isolates were more susceptible than inducible isolates to 8 micrograms/ml of piperacillin, a difference that was eliminated with the addition of either beta-lactamase inhibitor. Twelve of 13 strains produced a beta-lactamase band in the pH range of 7.9-8.1; no differences in satellite patterns were noted between the two groups of organisms. Increased production of beta-lactamase in the absence of an inducer may account for piperacillin resistance in P. cepacia in children with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3540826     DOI: 10.1203/00006450-198611000-00026

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator.

Authors:  S Trépanier; A Prince; A Huletsky
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

2.  Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability.

Authors:  J L Burns; L A Hedin; D M Lien
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  Isolation and characterization of a penicillinase from Pseudomonas cepacia 249.

Authors:  A Prince; M S Wood; G S Cacalano; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

4.  Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia.

Authors:  J L Burns; D M Lien; L A Hedin
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  The Pseudomonas cepacia 249 chromosomal penicillinase is a member of the AmpC family of chromosomal beta-lactamases.

Authors:  R Proenca; W W Niu; G Cacalano; A Prince
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 6.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

7.  Salicylate-inducible antibiotic resistance in Pseudomonas cepacia associated with absence of a pore-forming outer membrane protein.

Authors:  J L Burns; D K Clark
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.

Authors:  H Mentec; J M Vallois; A Bure; A Saleh-Mghir; F Jehl; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

9.  Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates.

Authors:  S C Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.